Gilead Sciences, Inc. (GILD)

60.03
NASDAQ
Prev Close 59.50
Day Low/High 59.28 / 60.06
52 Wk Low/High 57.04 / 85.97
Exchange NASDAQ
Shares Outstanding 1253.53B
Market Cap 74.58B
P/E Ratio 60.71
Div & Yield N.A. (N.A)

Latest News

Election Hopes, Buoyant Banks, Labor Labors Less, FDA's Remdesivir Thumbs Up

Election Hopes, Buoyant Banks, Labor Labors Less, FDA's Remdesivir Thumbs Up

Plus, a quick look at Southwest Airlines and why it remains the one airline to own.

A 4.5% Dividend Stock Trading at a Healthy Discount

A 4.5% Dividend Stock Trading at a Healthy Discount

The stock is simply too cheap, given its strong results to begin 2020, and a highly profitable business model that generates huge amounts of cash flow.

Where Does This Broad Rally Go? Q3 Earnings Begin, Amazon's Prime Day, Apple 5G

Where Does This Broad Rally Go? Q3 Earnings Begin, Amazon's Prime Day, Apple 5G

What stocks do from here will, beyond electoral risk and potential stimulus, rely upon fourth quarter guidance.

Should You Invest in Regeneron, Lilly, or Gilead?

Should You Invest in Regeneron, Lilly, or Gilead?

Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Real Money Post Industrial Average Outperforms Major Indexes in September

Real Money Post Industrial Average Outperforms Major Indexes in September

The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.

Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics

Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics

The short-term story for financial markets has been all about fiscal policy. This remains true.

Jim Cramer: It's Not Just About Stocks, I'm Sticking to What Matters

Jim Cramer: It's Not Just About Stocks, I'm Sticking to What Matters

I don't care for Washington but I have no choice. If I only stick to stocks, I would have buried you.

The Investment Angle of Covid-19

The Investment Angle of Covid-19

Stocks of companies that have Covid-19 vaccine candidates have boomed while those in the treatment space have not.

2 Dinged Biotech Stocks That Could Reward Investors in the Months Ahead

2 Dinged Biotech Stocks That Could Reward Investors in the Months Ahead

Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff

Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.

The Best Way to Navigate This Market

The Best Way to Navigate This Market

As is so often the case, the bears are unable to close the deal when it looks like they have an edge.

Jim Cramer: Is This Market Undervalued?

Jim Cramer: Is This Market Undervalued?

Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.

How About That Merck and Seattle Genetics Deal?

How About That Merck and Seattle Genetics Deal?

I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.

Spate of Deal News Juices Start of This Week's Trading

Spate of Deal News Juices Start of This Week's Trading

We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.

Jim Cramer: Sorry to Burst Your Bubble, but the Fed Bubble Talk Isn't True

Jim Cramer: Sorry to Burst Your Bubble, but the Fed Bubble Talk Isn't True

The Fed's money pumping has elevated new tech, but Jay Powell and the government haven't done any favors for many other stocks.

2 Candidates to Consider as Biotech Buyout Activity Picks Up

2 Candidates to Consider as Biotech Buyout Activity Picks Up

A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Here's How I'm Trading XBiotech

Here's How I'm Trading XBiotech

Do these shares get back to the 2020 highs that were reached back in January?

Bearish Bets: 2 Well-Known Stocks You Should Consider Shorting This Week

Bearish Bets: 2 Well-Known Stocks You Should Consider Shorting This Week

These familiar names are displaying both technical and quantitative deterioration.

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

Big Tech's Big Night, Eyeing Amazon, My Kodak Moment, Powell's Blunt Assessment

The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.

Gilead Sciences Could Dip a Little in Reaction to Earnings

Gilead Sciences Could Dip a Little in Reaction to Earnings

The charts are looking soft right now.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Charting the Stocks of 3 Covid Treatment Companies

Charting the Stocks of 3 Covid Treatment Companies

Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.

Gilead Sciences Is Set to Break Out: How to Play It

Gilead Sciences Is Set to Break Out: How to Play It

The stock is trading above the 50-day and the 200-day moving averages.

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average

The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.